Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Labeling for Pediatric MRI
By A Mystery Man Writer
Description
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug Administration (FDA) approval for an extension to include magnetic resonance imaging (MRI) of the central nervous system (CNS) in pediatric patients younger than 2 years of age (including term neonates). The agent may now be used in this patient population to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine and associated tissues.
IJMS, Free Full-Text
Episode 8: Gadolinium-Based Contrast Agents (GBCAs) Use in Pediatric MRI
Pull linear MRI contrast from market, European group says
The Use of Contrast-enhanced MRI in At-risk Patient Populations • APPLIED RADIOLOGY
A liposomal Gd contrast agent does not cross the mouse placental barrier
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
MultiHance - BraccoMR
Bracco Launches CT Exprès 3-D Contrast Media Delivery System at RSNA 2016
FDA Expands Labeling of MultiHance for Magnetic Resonance Angiography
Bracco Diagnostics Imaging Technology News
from
per adult (price varies by group size)
:max_bytes(150000):strip_icc()/IV-Contrast-Fluid-Shortage-GettyImages-984023466-2000-9682249d75064759982ddda274600dee.jpg)
